chenodeoxycholic acid has been researched along with incretins in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansen, JS; Hansen, M; Holst, JJ; Knop, FK; Rehfeld, JF; Scheltema, MJ; Sonne, DP; Sperling, M; Vilsbøll, T | 1 |
| Hameed, B; Terrault, N | 1 |
| Rotman, Y; Sanyal, AJ | 1 |
| Chalasani, N; Gawrieh, S | 1 |
3 review(s) available for chenodeoxycholic acid and incretins
| Article | Year |
|---|---|
Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antioxidants; Caspase Inhibitors; Chenodeoxycholic Acid; Cholic Acids; Fatty Acids, Omega-3; Humans; Incretins; Insulin Resistance; Liraglutide; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Pectins; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Topics: Anti-Obesity Agents; Antioxidants; Chenodeoxycholic Acid; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Drug Repositioning; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Incretins; Lipogenesis; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Tumor Necrosis Factor-alpha | 2017 |
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Topics: Antibodies, Monoclonal, Humanized; CCR5 Receptor Antagonists; Chalcones; Chenodeoxycholic Acid; Clinical Trials, Phase II as Topic; Cysteamine; Cystine Depleting Agents; Humans; Imidazoles; Incretins; Liraglutide; Non-alcoholic Fatty Liver Disease; Propionates; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sulfoxides | 2018 |
1 trial(s) available for chenodeoxycholic acid and incretins
| Article | Year |
|---|---|
Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Topics: Aged; Bile Acids and Salts; Blood Glucose; C-Peptide; Chenodeoxycholic Acid; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Placebos | 2016 |